Amebiasis: from parasitic biology to vaccine development
DOI:
https://doi.org/10.34119/bjhrv8n6-165Keywords:
amebiasis, Entamoeba histolytica, parasitic diseases, medical educationAbstract
Introduction: Amebiasis is a globally relevant parasitic disease with significant impact in developing countries. Its etiological agent, Entamoeba histolytica, is highly pathogenic and can cause both intestinal and extraintestinal manifestations. Although widely prevalent, most infections remain asymptomatic, which hinders early control and diagnosis. Objectives: To update the main concepts related to amebiasis, including: biology of the parasite, pathophysiology, diagnosis, clinical management, and prevention strategies. Methodology: Narrative literature review based on recent scientific articles published in databases such as PubMed, SciELO, and reference literature in medical parasitology. Discussion: Amebiasis remains one of the leading lethal parasitic diseases, especially in settings with poor sanitation. Transmission through contaminated water and food, clinical variability, and high morbidity in invasive cases reinforce the need for preventive measures. Furthermore, the importance of professional training for differential diagnosis and appropriate treatment is emphasized, particularly in areas with limited infrastructure. Conclusion: A thorough understanding of amebiasis is essential not only for individual clinical practice but also for the planning of public health policies. Strengthening medical education and epidemiological surveillance is a key strategy to reduce the impact of this neglected disease.
References
ABHYANKAR, Mayuresh M. et al. Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica. NPJ Vaccines, [S.l.], v. 3, n. 1, p. 1–1, 5 jun. 2018. Springer Science and Business Media LLC. Available at: http://dx.doi.org/10.1038/s41541-018-0060-x. Accessed on: July 22, 2025.
ABHYANKAR, Mayuresh M. et al. Immunogenicity and safety of an Entamoeba histolytica adjuvanted protein vaccine candidate (LecA+GLA-3M-052 liposomes) in rhesus macaques. Human Vaccines & Immunotherapeutics, [S.l.], v. 20, n. 1, p. 2374147, 31 dez. 2024. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11296537/. Accessed on: July 22, 2025.
ABHYANKAR, Mayuresh M. et al. Optimizing a multi-component intranasal Entamoeba histolytica vaccine formulation using a design of experiments strategy. Frontiers in Immunology, [S.l.], v. 12, p. 1–1, 25 jun. 2021. Frontiers Media SA. Available at: http://dx.doi.org/10.3389/fimmu.2021.683157. Accessed on: July 22, 2025.
ALMEIDA, Amanda Andrade de; LEITE, Tailana Santana Alves. Entamoeba histolytica como causa da amebíase. Revista Saúde e Meio Ambiente – Resma, Três Lagoas, v. 10, n. 1, p. 133–139, jul. 2020. Available at: https://periodicos.ufms.br/index.php/sameamb/article/view/9941. Accessed on: July 27, 2025.
CDC - CENTERS FOR DISEASE CONTROL AND PREVENTION. Amebiasis. In: CDC Yellow Book 2024: Health Information for International Travel. 2024. Available at: https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/amebiasis. Accessed on: July 12, 2025.
CHATTERJEE, Dipankor et al. A multi-epitope based vaccine against the surface proteins expressed in cyst and trophozoite stages of parasite Entamoeba histolytica. Journal of Immunological Methods, [S.l.], v. 517, p. 113475, jun. 2023. Elsevier BV. Available at: http://dx.doi.org/10.1016/j.jim.2023.113475. Accessed on: August 11, 2025.
CHOU, Arthur; AUSTIN, Richard L. Entamoeba histolytica infection. StatPearls, 17 abr. 2023. Available at: www.ncbi.nlm.nih.gov/books/NBK557718/. Accessed on: July 14, 2025.
COONEY, Joseph et al. Recent advances in the diagnosis and management of amoebiasis. Frontline Gastroenterology, [S.l.], v. 16, n. 1, p. 37–50, 7 out. 2024. BMJ. Available at: http://dx.doi.org/10.1136/flgastro-2023-102554. Accessed on: July 25, 2025.
DHAWAN, V. K. Amebiasis Treatment & Management. Medscape, 11 dez. 2024. Available at: https://emedicine.medscape.com/article/212029-treatment. Accessed on: July 25, 2025.
GONZALES, Maria Liza M. et al. Antiamebic drugs for treating amebic colitis. Cochrane Database of Systematic Reviews, [S.l.], 9 jan. 2019. Wiley. Available at: http://dx.doi.org/10.1002/14651858.cd006085.pub3. Accessed on: August 9, 2025.
GUILLÉN, Nancy. Pathogenicity and virulence of Entamoeba histolytica, the agent of amoebiasis. Virulence, [S.l.], v. 14, n. 1, p. 0, 4 jan. 2023. Informa UK Limited. Available at: http://dx.doi.org/10.1080/21505594.2022.2158656. Accessed on: July 15, 2025.
HARRISON, Tinsley Randolph. Harrison's principles of internal medicine. 21st ed. New York: McGraw-Hill, c2022. 2 v. ISBN 978-1-264-26846-7. Accessed on: July 12, 2025.
MARTÍNEZ-HERNÁNDEZ, Sandra L. et al. Evaluation of the PEΔIII-LC3-KDEL3 chimeric protein of Entamoeba histolytica-lectin as a vaccine candidate against amebic liver abscess. Journal of Immunology Research, [S.l.], v. 2021, p. 1–12, 20 mar. 2021. Wiley. Available at: http://dx.doi.org/10.1155/2021/6697900. Accessed on: August 16, 2025.
MORÁN, Patricia et al. Amoebiasis: advances in diagnosis, treatment, immunology features and the interaction with the intestinal ecosystem. International Journal of Molecular Sciences, [S.l.], v. 24, n. 14, p. 11755, 21 jul. 2023. MDPI AG. Available at: http://dx.doi.org/10.3390/ijms241411755. Accessed on: July 27, 2025.
MURPHY, Brynn M. et al. Intranasal delivery of a synthetic Entamoeba histolytica vaccine containing adjuvant (LecA + GLA-3M−052 liposomes): in vitro characterization. International Journal of Pharmaceutics, [S.l.], v. 626, p. 122–141, out. 2022. Elsevier BV. Available at: http://dx.doi.org/10.1016/j.ijpharm.2022.122141. Accessed on: August 18, 2025.
SIQUEIRA-BATISTA, R; GOMES, AP; SILVA SANTOS, S; SANTANA, LA. Parasitologia: fundamentos e prática clínica. 1. ed. Rio de Janeiro: Guanabara Koogan, 2020. Accessed on: July 12, 2025.
TEXAS DEPARTMENT OF STATE HEALTH SERVICES. Amebiasis: prevention and control measures. Jan. 2018. Available at: https://www.dshs.texas.gov/sites/default/files/IDCU/disease/amebiasis/Amebiasis-Prevention-and-Control.pdf. Accessed on: July 18, 2025.
U.S. DEPARTMENT OF DEFENSE – PUBLIC HEALTH. Amebiasis: Public Health Reference Sheet. 2023. Available at: https://phc.amedd.army.mil/PHC%20Resource%20Library/Amebiasis_FS_18-065-0719.pdf. Accessed on: July 18, 2025.
VALENCIANO, Lorena Batista et al. Amebíase: revisão bibliográfica acerca da fisiopatologia e manifestações clínicas. Brazilian Journal of Health Review, [S.l.], v. 7, n. 10, p. 0, 16 dez. 2024. Brazilian Journals. Available at: http://dx.doi.org/10.34119/bjhrv7n10-092. Accessed on: July 24, 2025.
